AR007097A1 - Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. - Google Patents
Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento.Info
- Publication number
- AR007097A1 AR007097A1 ARP970101977A ARP970101977A AR007097A1 AR 007097 A1 AR007097 A1 AR 007097A1 AR P970101977 A ARP970101977 A AR P970101977A AR P970101977 A ARP970101977 A AR P970101977A AR 007097 A1 AR007097 A1 AR 007097A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- matrix
- matrix metaloprotease
- biarylacetilene
- biarylacethylene
- Prior art date
Links
- 239000011159 matrix material Substances 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010053555 Arthritis bacterial Diseases 0.000 abstract 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010053177 Epidermolysis Diseases 0.000 abstract 1
- 208000004575 Infectious Arthritis Diseases 0.000 abstract 1
- 206010060820 Joint injury Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000028911 Temporomandibular Joint disease Diseases 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 201000007717 corneal ulcer Diseases 0.000 abstract 1
- 208000002528 coronary thrombosis Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000001223 septic arthritis Diseases 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Se presentan compuestos inhibitorios de la metaloproteasa de matriz, composiciones farmacéuticas de los mismos y el uso de dichos compuestos parapreparar un medicamento útil. Los compuestos tienen la fórmula (I), donde R15 es seleccionadoen tre el grupo que consiste en HOCH2, MeOCH2, (n-Pr)2NCH2,CH3CO2CH2, EtOCO2CH2, HO(CH2)2, CH3CO2(CH2)2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4, 3-HO-Ph, y PhCH2OCH2; y R16 es seleccionado entre las fórmulas (II). Estoscompuestos son útiles para inhibirlas m etaloproteasas de matriz y, por lo tanto, para combatir los trastornos a los cuales contribuyen las MMP, talescomo la osteoartritis, la artritis reumatoidea, la artritis séptica, las enfermedades periodontales, las úlceras decórnea, la p roteinuria, laenfermedad de aneurisma aórtico, la epidermólisis vesicular distrófica, los tratarnos que producen respuestas inflamatorias, las osteopenias en las quemedia la actividad de MMP, la enfermedad de la articulacióntemporomandibular, l as enfermedades desmielinizantes del sistema nervioso; las metástasis detumores o la pérdida degenerativa de cartílago posterior a la lesión articular traumática, y la trombosis coronaria a partir de la ruptura deplacaateroesclerótica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64502896A | 1996-05-15 | 1996-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007097A1 true AR007097A1 (es) | 1999-10-13 |
Family
ID=24587368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101977A AR007097A1 (es) | 1996-05-15 | 1997-05-12 | Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0912496A1 (es) |
| JP (1) | JP3090957B2 (es) |
| CN (1) | CN1139570C (es) |
| AR (1) | AR007097A1 (es) |
| AU (1) | AU710759B2 (es) |
| BR (1) | BR9709077A (es) |
| CA (1) | CA2253796C (es) |
| CO (1) | CO5080759A1 (es) |
| HN (1) | HN1997000088A (es) |
| HR (1) | HRP970245B1 (es) |
| ID (1) | ID16910A (es) |
| PA (1) | PA8429301A1 (es) |
| SV (1) | SV1997000035A (es) |
| TN (1) | TNSN97084A1 (es) |
| TW (1) | TW381079B (es) |
| WO (1) | WO1997043245A1 (es) |
| YU (1) | YU18697A (es) |
| ZA (1) | ZA974031B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
| AR035478A1 (es) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
| US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
| HUE030114T2 (en) * | 2010-07-08 | 2017-04-28 | Kaken Pharma Co Ltd | N-hydroxyformamide derivatives and pharmaceutical compositions containing them |
| JP2017509665A (ja) | 2014-04-03 | 2017-04-06 | バイエル ファーマ アクチエンゲゼルシャフト | 気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類 |
| US20170022171A1 (en) | 2014-04-03 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentanecarboxylic acids and their use |
| US20170119776A1 (en) | 2014-04-03 | 2017-05-04 | Bayer Pharma Aktiengesellschaft | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3784701A (en) * | 1970-09-21 | 1974-01-08 | American Cyanamid Co | Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain |
| DE2112716A1 (de) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester |
| FR2378741A1 (fr) | 1977-02-01 | 1978-08-25 | Fabre Sa Pierre | Acides garyl goxo isovaleriques doues de proprietes antiphlogistiques et antalgiques |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| ZA974033B (en) | 1996-05-15 | 1998-02-19 | Bayer Ag | Substituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors. |
-
1997
- 1997-05-09 HR HR970245A patent/HRP970245B1/xx not_active IP Right Cessation
- 1997-05-09 CO CO97025172A patent/CO5080759A1/es unknown
- 1997-05-09 ZA ZA9704031A patent/ZA974031B/xx unknown
- 1997-05-09 TN TNTNSN97084A patent/TNSN97084A1/fr unknown
- 1997-05-12 CA CA002253796A patent/CA2253796C/en not_active Expired - Fee Related
- 1997-05-12 JP JP09540980A patent/JP3090957B2/ja not_active Expired - Fee Related
- 1997-05-12 PA PA19978429301A patent/PA8429301A1/es unknown
- 1997-05-12 TW TW086106283A patent/TW381079B/zh not_active IP Right Cessation
- 1997-05-12 EP EP97923622A patent/EP0912496A1/en not_active Withdrawn
- 1997-05-12 AR ARP970101977A patent/AR007097A1/es unknown
- 1997-05-12 HN HN1997000088A patent/HN1997000088A/es unknown
- 1997-05-12 AU AU29386/97A patent/AU710759B2/en not_active Ceased
- 1997-05-12 WO PCT/US1997/007921 patent/WO1997043245A1/en not_active Ceased
- 1997-05-12 YU YU18697A patent/YU18697A/sr unknown
- 1997-05-12 BR BR9709077A patent/BR9709077A/pt not_active Application Discontinuation
- 1997-05-12 CN CNB971964564A patent/CN1139570C/zh not_active Expired - Fee Related
- 1997-05-12 SV SV1997000035A patent/SV1997000035A/es unknown
- 1997-05-14 ID IDP971606A patent/ID16910A/id unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ID16910A (id) | 1997-11-20 |
| JP3090957B2 (ja) | 2000-09-25 |
| JPH11511179A (ja) | 1999-09-28 |
| ZA974031B (en) | 1998-02-19 |
| BR9709077A (pt) | 1999-08-03 |
| CN1139570C (zh) | 2004-02-25 |
| CO5080759A1 (es) | 2001-09-25 |
| HRP970245A2 (en) | 1998-04-30 |
| AU710759B2 (en) | 1999-09-30 |
| TNSN97084A1 (fr) | 2005-03-15 |
| TW381079B (en) | 2000-02-01 |
| CA2253796A1 (en) | 1997-11-20 |
| WO1997043245A1 (en) | 1997-11-20 |
| CA2253796C (en) | 2003-10-28 |
| YU18697A (en) | 1999-11-22 |
| SV1997000035A (es) | 1999-01-14 |
| PA8429301A1 (es) | 2000-05-24 |
| HN1997000088A (es) | 1997-06-18 |
| CN1225623A (zh) | 1999-08-11 |
| AU2938697A (en) | 1997-12-05 |
| HRP970245B1 (en) | 2002-06-30 |
| EP0912496A1 (en) | 1999-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2166823T3 (es) | Nuevos derivados pirrolicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| ATE208397T1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| ATE288897T1 (de) | Polymorphische kristalline formen von celekoxib | |
| BR9611015A (pt) | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto | |
| AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
| ES2181803T3 (es) | Acidos 4-biarilbutiricos o 5-biarilpentanoicos sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz. | |
| ES2185750T3 (es) | Derivados de acido hidroxamico utiles para la inhibicion gelatinasa. | |
| BR9509683A (pt) | Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto | |
| AR007097A1 (es) | Biarilacetilenos inhibidores de la metaloproteasa de matriz, una composicion que tiene actividad inhibitoria de la metaloproteasa de matriz yel uso de dichos biarilacetilenos en la manufactura de un medicamento. | |
| AR010894A1 (es) | Aminoacidos aromaticos biciclicos, un procedimiento para prepararlos, preparaciones farmaceuticas que lo contienen y el empleo de los mismos parapreparar un medicamento que actua como inhibidor de la integrina. | |
| EA200200520A1 (ru) | Производные гетероциклоалкилсульфонилпиразола в качестве противовоспалительных/анальгетических агентов | |
| ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
| BG102471A (en) | Aromatic ketoacids and their derivatives as inhibitors of matrix metalloproteinases | |
| AR007098A1 (es) | Inhibidores de la metaloproteasa de matriz, composiciones que los comprenden, y uso de los mismos para preparar composiciones farmaceuticas | |
| MX9307608A (es) | Inhibidores de la liberacion de la citocina y antagonistas de la il-1,procedimiento para su preparacion y composiciones farmaceuticas que loscontienen. | |
| ES2147629T3 (es) | Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene. | |
| ES2087623T3 (es) | Derivados de bencimidazol como agente antimicrobiano contra campylobacter pylon. | |
| PA8429601A1 (es) | Inhibicion de las metaloproteinasas de matriz por acidos 2-(w-aroilalquil)-4-biaril-4-oxobutiricos. | |
| AR007100A1 (es) | Inhibicion de las metaloproteasas de matriz por compuestos de fenilalquilo sustituido y el uso de los mismos para la preparacion de un medicamento. | |
| AR007096A1 (es) | Compuesto inhibidor de la metaloproteasa de matriz metodo para inhibir su actividad, una composicion que lo contiene y uso de dichos compuestos para preparar composiciones farmaceuticas | |
| ATE40793T1 (de) | Pharmazeutisches praeparat zur therapeutischen behandlung von rheumatischen erkrankungen. | |
| MX9206042A (es) | Nuevos derivados de tiadiazinonas, proceso para su fabricacion y preparado farmaceutico que los contiene | |
| ECSP972114A (es) | Biarilacetilenos como inhibidores de la metaloproteasa de matriz | |
| ATE66208T1 (de) | Diarylmethan-sulfonamid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |